Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 6/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.32 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24735235 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1NOTUMGAAHPGD | |
| SCHEMBL24735338 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1NOTUMGAAHPGD | |
| SCHEMBL22505554 | 0.91 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1GAAHPGDPDE3B | |
| SCHEMBL29889809 | 0.91 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1GAAHPGDPDE3B | |
| SCHEMBL24735181 | 0.88 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1GAAHPGDPDE3B | |
| SCHEMBL28214218 | 0.77 | NOTUM (0.38) | NOTUMACACBMAPTHTT | |
| SCHEMBL6668947 | 0.76 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1GAAHPGDACACB | |
| Hydrochloric Acid SCHEMBL1836445 | 0.75 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1GAAHPGDACACB | |
| SCHEMBL24735234 | 0.74 | SYK (0.39) | SMN1; SMN2NOTUMGAAHPGDACACB | |
| SCHEMBL24735592 | 0.74 | SYK (0.39) | SMN1; SMN2NOTUMGAAHPGDACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117042769-A | Substituted pyrrolopyrimidines and pyrazolopyrimidines as Bruton's Tyrosine Kinase (BTK) degrading agents | 冰洲石生物科技公司 | 2023-11-10 | — | — | CN | disclosed |
| US-11530222-B2 | Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530222-B2 | Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders | BTK, LYN, SYK | SMN1; SMN2 3322/4885ALDH1A1 2925/4885NOTUM 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.